Tyrosine Kinase Inhibitors: all 10,744 studies that test it
Page 82 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.
- Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)Status unknownNCT02596256Phase 2
- Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)TerminatedNCT02595840Phase 2
- Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck CancerWithdrawnNCT02593929Early Phase 1
- Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+TerminatedNCT02593708Phase 1
- Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer PatientsCompletedNCT02593019Phase 2
- Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid TumorsCompletedNCT02592785Phase 1
- Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicable
- A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02590965Phase 2
- A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid TumorsCompletedNCT02590952Phase 1
- Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine TumorsCompletedNCT02589821Phase 3
- Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02588677Phase 2/3
- Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine TumorsCompletedNCT02588170Phase 3
- Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)CompletedNCT02586350Phase 2/3
- Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)Status unknownNCT02586337Phase 2/3
- Pharmacokinetics Study in Patients With Impaired Hepatic FunctionCompletedNCT02586194Phase 1
- Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCCCompletedNCT02585973Phase 1
- Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyActive, not recruitingNCT02584933Phase 4
- A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in MyelofibrosisWithdrawnNCT02584777Phase 2
- Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)Active, not recruitingNCT02584478Phase 3
- REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological ProgressionCompletedNCT02584465Phase 2
- Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal DiseaseCompletedNCT02581124Phase 1
- Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02580708Phase 1/2
- The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential ThrombocythemiaActive, not recruitingNCT02577926Phase 2
- Study of the Combination of CM082 With Everolimus in Patients With mRCCStatus unknownNCT02577458Phase 1
- A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedNCT02576431Phase 2
- Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic CancerWithdrawnNCT02575508Phase 1/2
- Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma PatientsTerminatedNCT02575066Phase 2
- Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis PatientsCompletedNCT02574091Phase 1
- A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215CompletedNCT02571816Phase 1
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesCompletedNCT02571036Phase 1
- PPI And Food Effect Study For PF-06463922 In Healthy VolunteersCompletedNCT02569554Phase 1
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingNCT02568267Phase 2
- An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural PerspectiveCompletedNCT02566967Phase 3
- A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male VolunteersCompletedNCT02564562Phase 1
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast CancerActive, not recruitingNCT02562118Phase 1/2
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesCompletedNCT02561988Phase 1
- A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PatientsCompletedNCT02558816Phase 1/2
- Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and NeckStatus unknownNCT02558387Phase 2
- Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)TerminatedNCT02558348Phase 1/2
- A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02556892Phase 1
- IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain MetastasesTerminatedNCT02556593Phase 2
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaCompletedNCT02555748Phase 4
- Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)WithdrawnNCT02554344Early Phase 1
- Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic SyndromeCompletedNCT02553941Phase 1
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
- Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced CancerCompletedNCT02546531Phase 1
- A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR PathwayCompletedNCT02544997Phase 2
- Apatinib for Metastatic Esophageal Cancer.Status unknownNCT02544737Phase 2
- Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular LymphomaCompletedNCT02542514Phase 2
- Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung CancerStatus unknownNCT02540824Phase 2
- Relative Bioavailability of Sorafenib Tablet for Oral SuspensionCompletedNCT02538393Phase 1
- Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric CancerStatus unknownNCT02537171Phase 3
- Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical ResectionStatus unknownNCT02537158Not applicable
- MSC2364447C Phase 1b in Systemic Lupus ErythematosusCompletedNCT02537028Phase 1
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus ErythematosusCompletedNCT02535689Phase 1
- Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung CancerStatus unknownNCT02535507Phase 2
- Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy VolunteersCompletedNCT02533102Phase 1
- The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine PatientsStatus unknownNCT02532023Phase 4
- Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung CancerCompletedNCT02531737Phase 2
- Bioequivalence Evaluation of a New and Current Tablet of ASP015KCompletedNCT02531191Phase 1
- Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast CancerStatus unknownNCT02530411Phase 2
- Curcumin Supplementation and Patients With Type 2 DiabetesCompletedNCT02529982Not applicable
- Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 DiabetesStatus unknownNCT02529969Phase 2/3
- TACE With or Without Sorafenib in Intermediate Stage Hepatocellular CarcinomaStatus unknownNCT02529761Not applicable
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
- Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric CancerStatus unknownNCT02525237Phase 2
- Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 2
- Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02520778Phase 1
- A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid TumorsCompletedNCT02520752Phase 1
- Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02518802Phase 3
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT02518555Phase 2
- The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung CancerStatus unknownNCT02515435Phase 2
- Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of AfatinibStatus unknownNCT02511847Phase 2
- AZD1775 Combined With Olaparib in Patients With Refractory Solid TumorsCompletedNCT02511795Phase 1
- A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP PatientsStatus unknownNCT02511340Phase 2
- Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer CellsStatus unknownNCT02510469Phase 2/3
- Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric CancerStatus unknownNCT02509806Phase 2/3
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Phase 1
- WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and NeckCompletedNCT02508246Phase 1
- A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER GeneCompletedNCT02506517Phase 2
- Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular CarcinomaStatus unknownNCT02504983Phase 4
- AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational StudiesStatus unknownNCT02504346Phase 2
- Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02503722Phase 1
- A Study of HMPL-523 in Relapsed or Refractory Hematologic MalignanciesStatus unknownNCT02503033Phase 1
- Afatinib, Paclitaxel, 2nd Line, Advanced Gastric CancerCompletedNCT02501603Phase 2
- Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line TherapyStatus unknownNCT02501551Phase 2
- A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR MutationsTerminatedNCT02500927Phase 2
- Phase I Study of Pyrotinib in Patients With HER2-positive Solid TumorsStatus unknownNCT02500199Phase 1
- Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory MalignanciesCompletedNCT02499861Phase 1/2
- Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)Status unknownNCT02499614Phase 2
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingNCT02496663Phase 1
- A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)CompletedNCT02495519Phase 2
- Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or OlderActive, not recruitingNCT02494882Phase 1
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedNCT02493530Phase 1
- Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer PatientsCompletedNCT02490488Phase 2/3
- Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell CarcinomaCompletedNCT02489695Phase 2
- Maintaining ERBB Blockade in EGFR-mutated Lung CancerTerminatedNCT02488694Phase 2
- A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With CrizotinibWithdrawnNCT02487316Phase 4
- Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With ChemotherapyCompletedNCT02486354Phase 3